|
DOSAGE
|
Implanted via intracameral injection
|
|
GENERIC
|
Bimatoprost 10 mcg implant
|
|
INDICATIONS
|
Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
|
|
MECHANISM OF ACTION
|
alpha-2 agonist | Bimatoprost is believed to lower IOP in humans by increasing outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional).
|
|
CONTRAINDICATIONS & WARNINGS
|
Durysta is contraindicated in patients with ocular or periocular infections, corneal endothelial cell dystrophy, prior corneal transplantation, absent or ruptured posterior lens capsule, and hypersensitivity to components of the product.
|
|
PEDIATRIC USE
|
Safety and effectiveness of DURYSTA in pediatric patients have not been established.
|
|
PREGNANCY
|
Pregnancy category C |There are no adequate and well-controlled studies of DURYSTA (bimatoprost intracameral implant) administration in pregnant women to inform a drug associated risk.
|
